Furthermore, pre-clinical studies using combined treatment with PTX and either a β-isoform-sparing PI3K inhibitor taselisib or pan-AKT inhibitor ipatasertib reduced proliferative and metastatic effects of breast cancer cells, as compared to either therapeutic strategy alone [9]. The gene discussed is PIK3CG; the disease is breast cancer.